Pendahuluan: Aneurisma adalah pembengkakan atau tonjolan abnormal pada dinding arteri. Lokasi aneurisma bervariasi, termasuk aneurisma serebral, aneurisma aorta toraks, dan aneurisma aorta abdomen. Aneurisma biasanya tidak menimbulkan gejala kecuali jika pecah. Kasus: Perempuan, berusia 32 tahun, dengan sakit kepala kronis selama 10 tahun terakhir. Hasil pemeriksaan mata menunjukkan peningkatan perbandingan diameter cup terhadap diskus saraf optik kedua mata tanpa tekanan intraokular yang meningkat. Hasil CT angiografi menunjukkan aneurisma pada segmen klinoid arteri karotis interna kiri dengan morfologi sakular, leher berukuran 4,39 mm, dan kubah berukuran 2,1 mm. Diskusi: Aneurisma intrakranial yang tidak pecah, glaukoma normotensi (NTG), dan sakit kepala kronis memiliki mekanisme disregulasi vaskular yang sama, seperti vasospasme dan gangguan aliran darah, yang mungkin menjelaskan manifestasi klinis yang tumpang tindih. Pada pasien ini, aneurisma segmen klinoid ICA kemungkinan berkontribusi pada sakit kepalanya yang kronis, dan mengobatinya dapat berpotensi meningkatkan frekuensi sakit kepala dan perubahan penglihatan terkait NTG. Simpulan: Karena ketidaktersediaannya peralatan pencitraan resonansi magnetik (MRI) dan ruang intervensi untuk angiografi subtraksi digital, kasus ini menyoroti kegunaan CT angiografi dalam mendiagnosis masalah anatomis, terutama pada kasus sakit kepala kronis, meskipun angiografi kateter masih dianggap sebagai standar emas. Pasien dirujuk untuk prosedur intervensi. Fabianus Anugrah Pratama, Petrus Sewe Pajo. Aneurisma Arteri Karotis Internal Kiri Segmen Klinoid pada Glaukoma Tekanan Normal dengan Nyeri Kepala Kronis.

Introduction: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality, and many patients present with intermediate or advanced disease. Transarterial chemoembolization (TACE) is an established treatment; however, its proangiogenic effects support the use of combination therapy. Combinations of TACE with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have shown a promising antitumor activity. The objective of this study was to describe post-treatment mRECIST response patterns of TACE alone, TACE plus lenvatinib and pembrolizumab, and TACE plus atezolizumab and bevacizumab for HCC. Methods: This multicentre retrospective, non-randomized pilot study included 25 consecutive patients with unresectable HCC treated with TACE alone (n = 10), TACE–lenvatinib–pembrolizumab (n = 7), or TACE–atezolizumab–bevacizumab (n = 8). The primary outcome was first post-treatment mRECIST response. ORR and DCR were calculated descriptively. Secondary outcomes included imaging interval, TACE exposure, repeat TACE, ALBI change, and OS, estimated using Kaplan–Meier methods. Results: Complete response, partial response, stable disease, and progressive disease occurred in 30.0%, 30.0%, 10.0%, and 30.0% after TACE alone, 14.3%, 28.6%, 57.1%, and 0% after TACE–lenvatinib–pembrolizumab, and 0%, 37.5%, 0%, and 62.5% after TACE–atezolizumab–bevacizumab. ORR/DCR were 60.0%/70.0%, 42.9%/100.0%, and 37.5%/37.5%, respectively. Median imaging intervals were 38.0, 25.0, and 20.0 months. ALBI-grade worsening occurred in 30.0%, 42.9%, and 37.5%; 1-year OS was 78.8%, 83.3%, and 50.0%, respectively. Conclusions: mRECIST response patterns were heterogeneous. Baseline liver-function imbalance, small groups, and non-randomized allocation preclude comparative efficacy inference. Larger prospective studies should standardize treatment sequencing, imaging, liver function assessment, safety monitoring, and survival evaluation.